Altaris Appoints Greg Sargen as Operating Partner

New York, NY—Altaris Capital Partners, LLC (collectively with its affiliates, “Altaris”) is pleased to announce the appointment of Greg Sargen as an Operating Partner. Mr. Sargen will support Altaris’ investment and portfolio company development activities in the pharmaceutical and pharma services sectors. Mr. Sargen currently serves as a Board Director and Audit Committee Chair for Kindeva Drug Delivery and Veranova, both Altaris portfolio companies.

Mr. Sargen has over twenty five years of experience in the pharmaceutical services industry and has served on the boards of two publicly traded biopharmaceutical companies. Previously, Mr. Sargen was with Cambrex Corporation, a global manufacturer and provider of services to life sciences companies, where he served as Executive Vice President and Chief Financial Officer, and as Executive Vice President of Corporate Development and Strategy. Prior to Cambrex, Mr. Sargen held various executive and finance leadership positions at several technology and healthcare companies, including Fischer Scientific International (now ThermoFisher) and Merck & Co. Mr. Sargen received a BS in Accounting from Pennsylvania State University and an MBA from The Wharton School at the University of Pennsylvania.

Altaris is a healthcare investment firm with an exclusive focus on building companies that deliver value to the healthcare system through innovation and efficiency. Since inception in 2003, Altaris has invested in more than 45 healthcare companies which have generated significant value appreciation for investors. Altaris is headquartered in New York City and manages over $5.0 billion of equity capital. For more information, please visit